Genetic susceptibility and oxidative stress in prostate cancer: Integrated model with implications for prevention

Urology

Volumn 68, Issue 6, 2006, Pages 1145-1151

  Klein, Eric A ^a   Casey, Graham ^a   Silverman, Robert ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CANCER VACCINE; CYCLOOXYGENASE 2 INHIBITOR; DUTASTERIDE; FINASTERIDE; GREEN TEA EXTRACT; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR; TUMOR PROTEIN; WART VIRUS VACCINE;

ANTIOXIDANT ACTIVITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CHROMOSOME; CLINICAL TRIAL; DNA DAMAGE; DRUG MECHANISM; EARLY CANCER; FAMILIAL CANCER; FAMILY; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENE THERAPY; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; INFECTION; INFECTION SENSITIVITY; INFLAMMATION; INFLAMMATORY DISEASE; INFLAMMATORY INFILTRATE; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROLIFERATIVE INFLAMMATORY ATROPHY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; RISK ASSESSMENT; UTERINE CERVIX CANCER;

ANDROGEN ANTAGONISTS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; OXIDATIVE STRESS; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 33845313312     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.08.1074     Document Type: Review

References (50)

1. Eeles R.A., Dearnaley D.P., Ardern-Jones A., et al. Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol 79 suppl 1 (1997) 8-14
2. Ahlbom A., Lichtenstein P., Malmstrom H., et al. Cancer in twins: genetic and nongenetic familial risk factors. J Natl Cancer Inst 89 (1994) 287-293
3. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 168 (2002) 906-913
4. Carter B.S., Bova G.S., Beaty T.H., et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150 (1993) 797-802
5. Gillanders E.M., Xu J., Chang B.L., et al. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 96 (2004) 1240-1247
6. Carpten J., Nupponen N., Isaacs S., et al. Germline mutations in the ribonuclease L (RNase L) gene in hereditary prostate cancer 1 (HPC1)-linked families. Nat Genet 30 (2002) 181-184
7. Tavtigian S.V., Simard J., Teng D.H., et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 27 (2001) 172-180
8. Xu J., Zheng S.L., Komiya A., et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 32 (2002) 321-325
9. Dong X., Wang L., Taniguchi K., et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72 (2003) 270-280
10. Edwards S.M., Kote-Jarai Z., Meitz J., et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72 (2003) 1-12
11. Marchesani M., Hakkarainen A., Tuomainen T.P., et al. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst 95 (2003) 812-818
12. Xu J., Zheng S.L., Turner A., et al. Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 62 (2002) 2253-2257
13. Lindmark F., Zheng S.L., Wiklund F., et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 96 (2004) 1248-1254
14. Zheng S.L., Augustsson-Balter K., Chang B., et al. Sequence variants of Toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 64 (2004) 2918-2922
15. Berthon P., Valeri A., Cohen-Akenine A., et al. Predisposing gene for early-onset prostate cancer, located on chromosome 1q42.2-43. Am J Hum Genet 62 (1998) 1416-1420
16. Gibbs M., Stanford J.L., McIndoe R.A., et al. Evidence for a rare prostate cancer susceptibility locus at chromosome 1p36. Am J Hum Genet 64 (1999) 776-780
17. Xu J., Meyers D., Freije D., et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 20 (1998) 175-178
18. Smith J.R., Freije D., Carpten J.D., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274 (1996) 1371-1374
19. Eeles R.A., Durocher F., Edwards S., et al. Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am J Hum Genet 62 (1998) 653-658
20. Silverman R.H. Implications for RNase L in prostate cancer biology. Biochemistry 42 (2003) 1805-1812
21. Xiang Y., Wang Z., Murakami J., et al. Effects of RNaseL mutations associated with prostate cancer on apoptosis induced by 2′,5′-oligoadenylates. Cancer Res 63 (2003) 6795-6801
22. Casey G., Neville P.J., Plummer S.J., et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32 (2002) 581-583
23. Rennert H., Zeigler-Johnson C.M., Addya K., et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev 14 (2005) 949-957
24. Maier C., Haeusler J., Herkommer K., et al. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer 92 (2005) 1159-1164
25. Wiklund F., Jonsson B.A., Brookes A.J., et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 10 (2004) 7150-7156
26. Malathi K., Paranjape J.M., Ganapathi R., et al. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2′,5′-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 64 (2004) 9144-9151
27. Goode E.L., Stanford J.L., Peters M.A., et al. Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci. Clin Cancer Res 7 (2001) 2739-2749
28. Gronberg H., Isaacs S.D., Smith J.R., et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 278 (1997) 1251-1254
29. Platt N., and Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional?. The mouse's tale. J Clin Invest 108 (2001) 649-654
30. Thomas C.A., Li Y., Kodama T., et al. Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J Exp Med 191 (2000) 147-156
31. Lemaitre B., Nicolas E., Michaut L., et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86 (1996) 973-983
32. O'Neill L.A., Fitzgerald K.A., and Bowie A.G. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 24 (2003) 286-290
33. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
34. De Winther M.P., Gijbels M.J., Van Dijk K.W., et al. Transgenic mouse models to study the role of the macrophage scavenger receptor class A in atherosclerosis. Int J Tissue React 22 (2000) 85-91
35. Boiteux S., and Radicella J.P. The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis. Arch Biochem Biophys 377 (2000) 1-8
36. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
37. Platz E.A., and De Marzo A.M. Epidemiology of inflammation and prostate cancer. J Urol 171 (2004) S36-S40
38. U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program: 11th Report on Carcinogens, 2005. Available at: http://ntp.niehs.nih.gov/ntp/roc/toc11.html. Accessed June 6, 2005.
39. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. N Engl J Med 349 (2003) 366-381
40. Dennis L.K., and Dawson D.V. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13 (2002) 72-79
41. Dennis L.K., Lynch C.F., and Torner J.C. Epidemiologic association between prostatitis and prostate cancer. Urology 60 (2002) 78-83
42. Samanta M., Harkins L., Klemm K., et al. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 170 (2003) 998-1002
43. Zambrano A., Kalantari M., Simoneau A., et al. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate 53 (2002) 263-276
44. De Marzo A.M., Marchi V.L., Epstein J.I., et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155 (1999) 1985-1992
45. Putzi M.J., and De Marzo A.M. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 56 (2000) 828-832
46. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. N Engl J Med 349 (2003) 366-381
47. Kumar-Sinha C., Shah R.B., Laxman B., et al. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol 164 (2004) 787-793
48. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
49. Andriole G.L., Roehrborn C., Schulman C., et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64 (2004) 537-541
50. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278